Canadian Pharmacist Advocates for Access to Nicotine Pouches

A recent discussion has sparked a debate about smoking cessation aids in Canada, particularly regarding the authorized nicotine pouch, Zonnic. Pharmacist Todd Prochnau has expressed concern over the criticisms directed at Zonnic by health advocates Cynthia Callard, Flory Doucas, and Les Hagen. Prochnau argues that limiting access to this Health Canada-approved product contradicts the goal of reducing tobacco-related illnesses.

Smoking is a known cause of serious health issues, including cancer and chronic lung diseases. For years, nicotine replacement therapy (NRT) has been a cornerstone in helping individuals quit smoking. The safety and efficacy of NRT are well-documented, and Zonnic is recognized within Canada as an approved cessation tool. Prochnau believes that all approved cessation therapies should be available to support patients.

The criticisms from Callard and her colleagues focus on three main points regarding nicotine pouches: their effectiveness, youth use, and the fact that Zonnic is produced by a tobacco company. The Canadian Community Health Survey notes that approximately 92% of users of tobacco-free nicotine pouches fail to quit, a figure that raises eyebrows. However, Prochnau highlights that the failure rates for all nicotine replacement products hover around 87%, with any method of quitting showing an 85% failure rate. This suggests that the data used to criticize nicotine pouches may be selective.

Prochnau emphasizes the need for well-designed controlled trials that compare nicotine pouches with other cessation therapies. The current evidence does not substantiate claims that nicotine pouches are less effective than traditional NRTs, making the focus on their effectiveness unwarranted.

Concerns about youth use also arise in the discussion. The International Tobacco Control (ITC) Youth Tobacco and Vaping Survey indicates that the most popular brands among youth are illicit products like Zyn and Lyft, which have no regulatory oversight in Canada. In contrast, Zonnic, the authorized product, is less frequently mentioned by youth. Prochnau argues that restricting access to regulated products does not eliminate demand; rather, it simply drives consumers to unregulated sources.

The third point of contention is the identity of Zonnic’s manufacturer. While it is produced by a tobacco company, Prochnau insists that the regulatory approval from Health Canada should take precedence over the manufacturer’s identity. He maintains that the focus should be on the product’s ability to help individuals quit smoking, rather than the company behind it.

Prochnau notes that nicotine pouches are gaining traction worldwide and are likely to remain available regardless of regulatory hurdles. He presents two policy options for Canada. The first is to allow authorized nicotine pouches to be sold through regulated outlets with age verification, similar to the systems in place for alcohol and cannabis. This would enable regulators to enforce standards and limit youth access while ensuring that adult smokers can access cessation products.

The second option involves continuing to restrict access to authorized nicotine pouches, which would ultimately benefit illicit suppliers who operate without age controls or limits on nicotine content. Prochnau points to Australia as a cautionary example, where strict regulations on legal vaping products have pushed a significant percentage of vapers into the illicit market, resulting in higher youth vaping rates than in Canada and the United States.

As a pharmacist, Prochnau has worked with many patients seeking to quit smoking. He stresses the importance of providing diverse options to support cessation efforts. A person-centred approach is vital; those trying to quit smoking should have access to a range of cessation aids available in pharmacies and retail stores. He believes that reducing tobacco-related illnesses hinges on ensuring that individuals have the necessary resources to quit successfully.

In summary, the debate surrounding nicotine pouches in Canada underscores the need for a balanced and evidence-based approach to smoking cessation. By allowing access to approved products like Zonnic, Canada could better support those seeking to quit smoking and ultimately reduce the burden of tobacco-related illnesses.